特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
319191

遺伝子検査の世界市場 - 種類、疾病、技術(細胞遺伝学的検査、生化学的検査、分子検査)、および地域別の成長率、動向および予測(2020年~2025年)

Genetic Testing Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 111 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
遺伝子検査の世界市場 - 種類、疾病、技術(細胞遺伝学的検査、生化学的検査、分子検査)、および地域別の成長率、動向および予測(2020年~2025年)
出版日: 2020年06月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 111 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

遺伝子検査市場はここ数年で急速な成長を遂げました。過去数年間からの技術の進歩は、市場拡大のためのいくつかの機会を切り開いてきました。慢性疾患の罹患率の上昇とニッチな治療分野向けのカスタマイズされた検査キットの開発は、市場の急速な成長を支えています。

当レポートでは、世界の遺伝子検査市場を調査し、全体的な市場動向、種類・疾病・技術・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

1 イントロダクション

  • 調査の成果
  • 調査の前提条件
  • 調査範囲

2 調査方法

3 エグゼクティブサマリー

4 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • 疾患の早期検出と予防を重要視する傾向
    • オーダーメード医療に対する需要の高まり
    • 腫瘍学における遺伝子検査の利用の増加
  • 市場の阻害要因
    • 遺伝子検査の高コスト
    • 遺伝子検査の社会的および倫理的意味
  • 業界の魅力 - ポーターのファイブフォース分析
    • 新規参入者の脅威
    • 買い手/消費者の交渉力
    • 売り手の交渉力
    • 代替製品の脅威
    • 業界内の競合の激しさ

5 市場セグメンテーション

  • 種類別
    • 保因者試験
    • 診断テスト
    • 新生児スクリーニング
    • 予測テストと事前テスト
    • 出生前診断
    • その他
  • 疾病別
    • アルツハイマー病
    • 嚢胞性線維症
    • 鎌状赤血球貧血
    • デュシェンヌ型筋ジストロフィー
    • サラセミア
    • ハンチントン病
    • まれな疾患
    • その他の病気
  • 技術別
    • 細胞遺伝学的検査
    • 生化学検査
    • 分子テスト
  • 地理
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

6 競合情勢

  • 企業プロファイル
    • Abbott Laboratories Inc.
    • Bio-Rad Laboratories
    • Danaher Corporation (Cepheid)
    • F. Hoffmann-La Roche Ltd
    • Illumina Inc.
    • 23andMe
    • Eurofins Scientific SE (Eurofins)
    • Genesis Healthcare
    • Luminex Corporation
    • Myriad Genetics Inc.
    • Precipio (Transgenomics Inc.)
    • Qiagen
    • Thermo Fisher Scientific Inc.

7 市場機会および将来動向

目次
Product Code: 50664

The genetic testing market has experienced a rapid growth in the past few years. The increasing technological advancements from the past few years have opened several opportunities for market expansion. The rise in the prevalence of chronic diseases and the development of customized testing kits for niche therapeutic areas are aiding the rapid growth of the market.

The increasing focus by governments of various countries, to regulate and create awareness regarding genetic tests, has successfully resulted in the faster adoption of these tests across the world. The increasing R&D funding, along with the strong market presence by major players in the market, has created a strong entry barrier for new entrants. Innovation in product design, improvement in quality, and strong distribution partnerships are key parameters to retain a competitive edge in the market.

The adoption of direct to consumer genetic testing kits in countries, like the United States, China, and Japan, is growing rapidly. With increasing technological adoptions, awareness programs, and a decline in costs, the market for DTC-GT (Direct-to-consumer genetic testing) kits is likely to witness a significant boost over the forecast period. Moreover, the untapped countries, like India and other developing countries, are expected to offer a lucrative opportunity for players looking to establish their base in the genetic testing market.

Key Market Trends

Application in Cancer is Expected to Dominate the Market

  • Genetic testing helps estimate the chance of developing cancer in a person's lifetime. It does this by searching for specific changes in genes, chromosomes, or proteins. Moreover, it helps in predicting risk of a particular type of cancer in a person and finding whether genes that may pass increased cancer risk to its next generation.
  • The global incidence of cancer is high and is expected to increase in future as well. Cancer Research UK 2018 data suggests that if recent trends in the incidence of major cancers and population growth are consistent, then it is expected that there may be 27.5 million new cancer cases across the world, annually, by 2040. This is an increase of 61.7% from 2018 (17 million new cases).
  • Increase in number of cancer cases is expected to increase the demand for genetic testing kits for early detection. This is likely to help the market growth.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

  • Currently, North America dominates the market for genetic testing, owing to factors, like increasing demand for personalized genetic testing services in the region and rise in the prevalence of chronic and genetic disorders.
  • In the United States, two federal agencies have the primary authority to regulate genetic tests, the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS). In the past, the Federal Trade Commission (FTC) has also played a role in regulating genetic testing companies, who advertised false and misleading claims about their products, but this agency currently plays a minor role in this space.​
  • The popular direct-to-customer genetic testing (DTC-GT) services available in the United States include those offered by 23&Me. These genetic testing services are largely unregulated, due to their mode of sales operation viz online marketplace.
  • In the developing regions, like Mexico, market players from neighboring countries, like United States, are penetrating the Mexican market, exploring untapped opportunities. Therefore, these factors are expected to help the growth in the North American region in the future.

Competitive Landscape

The genetic testing market is highly competitive and consists several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Abbott Laboratories, BioRad Laboratories Inc., F Hoffmann-La Roche, and Illumina Inc., is in turn, increasing the overall competitive rivalry of the market. The product advancements and improvements in genetic testing platforms by the major players are increasing competitive rivalry.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Emphasis on Early Disease Detection and Prevention
    • 4.2.2 Growing Demand for Personalized Medicine
    • 4.2.3 Increasing Application of Genetic Testing in Oncology
  • 4.3 Market Restraints
    • 4.3.1 High Costs of Genetic Testing
    • 4.3.2 Social and Ethical Implications of Genetic Testing
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Carrier Testing
    • 5.1.2 Diagnostic Testing
    • 5.1.3 Newborn Screening
    • 5.1.4 Predictive and Presymptomatic Testing
    • 5.1.5 Prenatal Testing
    • 5.1.6 Other Types
  • 5.2 By Disease
    • 5.2.1 Alzheimer's Disease
    • 5.2.2 Cancer
    • 5.2.3 Cystic Fibrosis
    • 5.2.4 Sickle Cell Anemia
    • 5.2.5 Duchenne Muscular Dystrophy
    • 5.2.6 Thalassemia
    • 5.2.7 Huntington's Disease
    • 5.2.8 Rare Diseases
    • 5.2.9 Other Diseases
  • 5.3 By Technology
    • 5.3.1 Cytogenetic Testing
    • 5.3.2 Biochemical Testing
    • 5.3.3 Molecular Testing
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 23&Me Inc.
    • 6.1.2 Abbott Laboratories
    • 6.1.3 BioRad Laboratories Inc.
    • 6.1.4 Danaher Corporation (Cepheid Inc.)
    • 6.1.5 F Hoffmann-La Roche AG
    • 6.1.6 Illumina Inc.
    • 6.1.7 Luminex Corporation
    • 6.1.8 Myriad Genetics Inc.
    • 6.1.9 PerkinElmer Inc.
    • 6.1.10 Quest Diagnostics Incorporated

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.